The mitogen-activated protein kinase (MAPK) cascades play a pivotal role in a myriad of cellular functions. The specificity and efficiency of MAPK signaling are controlled by docking interactions between MAPKs and their cognate proteins. Many MAPK-interacting partners, including substrates, MAPK kinases, phosphatases, and scaffolding proteins, have linear sequence motifs that mediate the interaction with the common docking site on MAPKs. We report the crystal structure of p38a in complex with the MAPK binding domain (KBD) from MAPK phosphatase 5 (MKP5) at 2.7 Å resolution. In contrast to the well-known docking mode, the KBD binds p38a in a bipartite manner, in which two distinct helical regions of KBD engage the p38a docking site, which is situated on the back of the p38a active site. We also determined the crystal structure of the KBD of MKP7, which closely resembles the MKP5 KBD, suggesting that the mechanism of molecular recognition by the KBD of MKP5 is conserved in the cytoplasmic p38-and c-Jun N-terminal kinase-specific MKP subgroup. This previously unknown binding mode provides new insights into how MAPKs interact with their binding partners to achieve functional specificity.
INTRODUCTION
The mitogen-activated protein kinase (MAPK) signaling pathways play an important role in cellular signal transduction (1) (2) (3) . There are 14 MAPKs in humans, which define seven distinct MAPK signaling pathways. The basic assembly of MAPK pathways is a three-tier kinase module that establishes a sequential activation cascade: a MAP kinase kinase kinase activates a MAP kinase kinase, which in turn activates a MAP kinase. Different MAPK modules respond to distinct extracellular stimuli. The three best-characterized MAPK signaling pathways are mediated by the kinases extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38. The ERK pathway is activated by various mitogens and phorbol esters, whereas the JNK and p38 pathways are stimulated mainly by environmental stress and inflammatory cytokines (2, 4, 5) . After activation, each MAPK phosphorylates a distinct spectrum of substrates, which include key regulatory enzymes, cytoskeletal proteins, nuclear receptors, regulators of apoptosis, and transcription factors.
The physiological outcome of MAPK signaling depends on both the magnitude and the duration of kinase activation. Modulation of MAPK activities in response to extracellular stimuli is mainly achieved by the coordinated action of protein kinases and phosphatases. Full activation of MAPKs requires dual phosphorylation of a Thr-X-Tyr sequence located on a flexible activation loop, where X is Glu in ERKs, Pro in JNKs, and Gly in p38s. Dual-specificity kinases termed MAPK kinases (MAPKKs) catalyze the dual phosphorylation of threonine and tyrosine residues in this sequence, resulting in an increase of more than 1000-fold in MAPK activity. In contrast, down-regulation of MAPK activity can be carried out by the dephosphorylation of these residues by various serine-threonine phosphatases, tyrosine phosphatases, and dual-specificity phosphatases termed MAPK phosphatases (MKPs). That MAPK activation is catalyzed by a single kinase and its inactivation involves multiple phosphatases suggests that the regulated dephosphorylation of MAPKs may play a crucial role in controlling cellular responses to external stimuli and determining the time course, threshold for activation, and hence the physiological outcome of signaling.
The specificity in the functional interactions between MAPKs and their cognate proteins appears to be generated by a common docking (CD) site in MAPKs for interaction partners that have docking motifs or D motifs [also referred to as kinase interaction motifs (KIMs)] (6) (7) (8) .
KIMs are found in all the MAPK interacting proteins, including phosphatases, substrates, and scaffolding proteins, as well as activating kinases. There are two major elements in nearly all the KIMs: a cluster of basic residues at the N terminus and a hydrophobic motif near the C terminus. Crystal structures of mammalian MAPKs bound with the KIM sequences derived from their interacting proteins have been reported (9) (10) (11) (12) (13) (14) . These structures revealed that linear docking motifs in interacting proteins bind to a CD site on MAPKs outside the kinase active site. The docking site is composed of a highly acidic patch and a hydrophobic groove, which mediate interactions with the basic and with the F A -X-F B residues, respectively, in the KIM sequences. Both variations in the number and position of hydrophobic and basic residues within KIM sequences and amino acid composition of the docking sites on MAPKs likely contribute to the pathway specificity among MAPK modules. Similarly, docking interactions were demonstrated for the complexes of yeast MAPKs, Fus3 and Kss1, with specific peptides, indicating that the mechanism of molecular recognition by the docking site is conserved evolutionarily in MAPK networks from yeast to mammals (15) .
To understand the molecular basis of p38a recognition by MAPK phosphatase 5 (MKP5), we have determined the crystal structure of p38a in complex with the MAPK binding domain (KBD) of MKP5. To our surprise, the nature of the interaction between p38a and KBD is fundamentally different from those of other MAPK complexes including MAPKs and both KIM peptides and their cognate partners. Thus, this structure reveals a new mode of docking interaction between MAPK and its cognate proteins, providing a hitherto unrecognized diversity of potential interaction partners for mediating and regulating the signal transduction by the MAPK cascades.
RESULTS

Interaction of p38a with KBD of MKP5
MKPs are crucial inhibitors of MAPK signaling because they dephosphorylate both phosphotyrosine and phosphothreonine in the activation loop of MAPKs. The MKPs constitute a structurally distinct subfamily of 10 catalytically active enzymes within the larger family of dual-specificity protein phosphatases (DUSPs) encoded in the human genome (16) . On the basis of sequence similarity, protein structure, substrate specificity, and subcellular localization, the MKP family can be further divided into three groups (17) . The first group is composed of four inducible nuclear MKPs: MKP1, MKP2, PAC1, and hVH3. The second group contains three closely related cytoplasmic ERK-specific phosphatases: MKP3, MKP4, and MKPX. The third group is composed of MKP5, MKP7, and hVH5, which selectively inactivate the stress-activated MAPKs JNK and p38. All MKPs share a common structure comprising a C-terminal catalytic domain and an N-terminal KBD (18) . Despite sequence divergence within KBD, a conserved KIM is present in the N-terminal region of all these MKPs. The KIM is characterized by a region rich in basic amino acids, followed by a F A -X-F B motif (where F is Leu, Ile, or Val), and plays an important role in MAPK substrate recognition and binding (Fig. 1A) .
MKP5, which belongs to the MKP family, preferentially inactivates p38 and JNK but not ERK (table S1) (19, 20) . MKP5 is unique among the MKPs in that it has an additional segment of unknown function at the N terminus (Fig. 1B) . Deletion of the KBD in MKP5 leads to a 400-fold increase in K m (Michaelis constant) for p38a substrate, but it has little effect (1.5-fold) on k cat , suggesting that the KBD of MKP5 is critical for p38a binding and efficient p38a dephosphorylation by MKP5 (21) . To test whether isolated KBD of MKP5 and p38a could form a stable binary complex in solution, we analyzed the binding of KBD with unphosphorylated and phosphorylated p38a by size exclusion chromatography (Fig. 1C) . The chromatographic profiles of unphosphorylated and phosphorylated p38a showed that both proteins eluted with a similar retention time, corresponding to a molecular mass of 43.5 kD as determined from the protein calibration curve. When 5 molar equivalents of KBD were mixed with 1 molar equivalent of p38a, a small amount of KBD was shifted to earlier fractions, forming stable complexes, and the excess amount of KBD was eluted from the size exclusion column as a monomer.
We used competitive binding assays to measure the binding affinity of the KBD of MKP5 for phosphorylated p38a. The initial rates of MKP5-catalyzed reaction were measured in the presence of various concentrations of p38a substrate and four different fixed concentrations of KBD. The initial velocity of MKP5 catalysis depended on the p38a concentration, and the KBD inhibited the MKP5 activity in a concentrationdependent manner (Fig. 1D) . Because the KBD of MKP5 binds p38a tightly, this inhibition probably reflects competition for p38a binding to full-length MKP5. The data sets of initial velocities were analyzed with a kinetic equation by global fitting procedure. The binding affinity of the KBD of MKP5 for phosphorylated p38a had a K i (inhibition constant) of 1.01 ± 0.01 mM.
Structure of p38a in complex with the KBD of MKP5
We solved the structure of the binary complex of unphosphorylated p38a bound to the KBD of MKP5 by molecular replacement (Fig.  2A) . The model of the heterodimer was refined at 2.7 Å resolution to an R factor of 21.6% (R free of 26.0%) with good stereochemistry (Table  1) . When bound to p38a, the KBD of MKP5 covers a contiguous surface area situated opposite of the p38a active site (Fig. 2B) . The docking site on p38a contains the previously identified (negatively charged) CD region and hydrophobic groove between helices aD and aE and the b7-b8 reverse turn (9, 22, 23) . We found that the interaction of the KBD of MKP5 with p38a mainly involved two helices, a2 and a3′, from the KBD. In the p38a-KBD complex, the conformation of KBD is similar to that of the isolated KBD of MKP5 (24) , except several residues local to the binding region undergo conformational changes upon binding ( fig.  S1 ). However, the structure of p38a in the present complex has some differences from the apo-p38a structure. The p38a structure of the present heterodimer superimposed on the apo-p38a (25, 26) with a root mean square deviation (RMSD) of 1.2 Å for equivalent C a atoms. The two lobes are rotated by 5.6°toward one another in p38a of the complex (Fig. 2C) . The activation loop exhibits perhaps the largest change on binding of the KBD. In the present complex structure, many of the residues of the activation loop, including Thr 180 and Tyr
182
, are crystallographically disordered (no electron density was visible for residues 170 to 183), suggesting that flexibility in the p38a activation loop caused by docking to the KBD could release this loop for binding to the active site of MKP5 and aid in dephosphorylation of p38a. Similar observation of enhanced disorder , residues 60 to 74) has been reported (11) . Like other known docking peptide complexes, such as p38a-KIM MKK3b and p38a-KIM
MEF2A
, the ERK2-KIM MKP3 complex reveals that this KIM peptide binds ERK2 in an extended conformation (Fig. 2D) . The polypeptide direction compared to how the KIM sequence of MKP3 binds to ERK2. The F A and F B residues in the proposed KIM of MKP5 do not participate in the interaction between p38a and MKP5. Instead, the KBD interacts with p38a in a bipartite manner, such that two distinct helical regions of KBD engage the p38a docking site situated on the back of the p38a active site.
The solution structure of the KBD (residues 1 to 154) from MKP3 has been determined by nuclear magnetic resonance (27) . Distinct structural differences are observed between the KBD of MKP5 and that of MKP3 (24, 27) . The KIM sequence that is important for ERK2-MKP3 interaction lies within different structural elements and is located at different positions in the two structures. The residues of KIM sequence in MKP3 are located in a flexible region connecting b3 and a3, whereas their sequence equivalents (residues 199 to 213) in MKP5 are located in a helix (a3′) and following loop region, on the opposite face of the central b sheet. Thus, the large structural differences may explain why the binding of MKP5 to p38a adopts an interaction mode different from that of other KIM peptides.
Mutational analysis of the p38a-MKP5 docking interface
On the basis of the crystal structure, we found that the KBD of MKP5 buries a total surface area of~920 Å in p38a. The KBD of MKP5 interacts with p38a through two major contact areas (Fig. 3A) . The first area is composed of the helix a3′ and the following a3′-a3 loop in the KBD of MKP5 and CD domain in p38a, an acidic patch involving Asp . By comparing the current structure with previous ones (9-11, 13-15), we find that the hydrophobic pocket, which accommodates the binding of the F A residue in ERK2-KIM MKP3 and other MAPK-KIM complex structures, is plugged into by two intervening residues, Phe 180 ′ and Met 181 ′, whereas the hydrophobic patch filled by the F B residue is unoccupied in the p38a-KBD MKP5 complex (Fig. 3D) . Although MK2 binds to the p38a hydrophobic groove in the same polypeptide direction as KBD MKP5 , the docking mode of MK2 is more similar to other known KIM peptides binding in the opposite direction, such as KIM MEF2A and KIM
MKK3b
, than KBD MKP5 (14) (fig. S3) . Thus, the docking of the KBD of MKP5 to p38a represents a previously unrecognized docking class.
To validate the binding mode between KBD MKP5 and p38a, we first examined the effects of KBD MKP5 -p38a interaction on the p38a activity toward both peptide substrate [epidermal growth factor receptor (EGFR) peptide] and KIM-containing substrate (ATF2D109). The initial velocity of the p38a-catalyzed reaction depends on the concentration of KBD MKP5 when ATF2D109 is used as substrate ( fig. S4 ). As expected, the enzyme activity of p38a for ATF2D109 decreased with increases in the concentration of KBD MKP5 , whereas KBD MKP5 had no effect on the p38a activity for EGFR peptide substrate because the EGFR peptide does not have a KIM domain. Using gel filtration assays, we also performed competitive binding experiments and found that KBD MKP5 disrupted the p38a-ATF2D109 and p38a-MKK6 complexes ( fig. S5 ). Together, our biochemical results suggest that the physical association of KBD MKP5 with p38a may generate a steric block that prevents binding of the KIM-containing partners.
To assess the importance of the aforementioned interactions, we generated a series of point mutations in the KBD of MKP5 and examined their effect on the MKP5-catalyzed p38a dephosphorylation (Fig.  3E) . When the hydrophobic residues Phe 180 and Met 181 on the a2 of the KBD were individually replaced by Ala, the catalytic efficiencies (k cat /K m ) of the F180A and M181A mutants for p38a dephosphorylation decreased four-and twofold, respectively. Compared to wild-type MKP5, replacement of both Phe 180 and Met 181 with an Ala led to an eightfold drop in the k cat /K m value. However, mutating these hydrophobic residues to charged Asp (F180D, M181D, or F180D and M181D) led to marked enzymatic inactivation (8-to 30-fold) (table S2) . Similarly, when the two basic residues, Arg 203 and Arg 204 , on the a3′ of KBD were individually replaced by an Ala, the catalytic efficiencies (k cat /K m ) of the mutants were decreased more than 10-fold, and substitution of both these Arg residues with Ala resulted in a further decrease (~150-fold) in k cat /K m , comparable to that observed in a mutant lacking the whole docking domain (MKP5DN319) (Fig. 3E and table S2 ). In addition, forms of MKP5 with mutations in crucial residues on the KBD interface, I200A and K209A, had decreased catalytic efficiencies. Mutations in the KBD of MKP5 caused an increase in K m but had a modest effect on k cat (table S2), supporting the notion that the major function of the KBD in MKP5 is to increase the effective concentration of the pT-X-pY motif in the vicinity of the active site of MKP5 for dephosphorylation. We also made mutations of two hydrophobic residues corresponding to F A and F B in the KIM sequence, I210A and V212A, as negative controls, and assessed their effect on catalytic function (Fig. 3E and table S2 ). As expected, these two mutants did not show altered catalytic efficiencies. Collectively, these data indicated that both the hydrophobic and the charged residues in the KBD of MKP5 are required for its high-affinity binding to the MAPK p38a.
Comparison of docking interactions among MKPs
MKP7 is specific for p38 and JNK but not ERK, and its unique structural feature is that it contains an additional sequence at the C terminus that is rich in prolines, glutamates, serines, and threonines (PEST) (Fig.  4A ) (28, 29) . Compared with MKP5, however, deletion of the N-terminal domain had only a modest effect on the phosphatase activity of MKP7 (~14-fold in k cat /K m ) (table S3) . Thus, it would be of interest to know whether the KBD of MKP7 can form a tight physical complex with p38a. To address this issue, we analyzed the interaction of unphosphorylated p38a with the KBD of MKP7 (residues 5 to 138) by gel filtration analysis and competitive binding assays. Gel filtration analysis indicated that p38a formed a stable heterodimer with the KBD of MKP7 in solution (Fig. 4B) . Consistent with MKP7 binding to p38a through its KBD, the enzymatic activity of MKP5 toward p38a substrate was inhibited in the presence of isolated MKP7 KBD (Fig. 4C) . The binding affinity of the MKP7 KBD for phosphorylated p38a had a K i of 0.74 ± 0.13 mM.
To gain a structural understanding of the interaction mode between p38a and MKP7, we crystallized the MKP7 KBD (residues 5 to 138) and determined its three-dimensional structure at 2.7 Å resolution (Fig.  5A ). There were four molecules of MKP7 KBD in each asymmetric unit; these four molecules exhibited identical structure and were superimposable with one another (fig. S6 ). The compact structure comprised a central b sheet of five parallel b strands, which was surrounded by three a helices on the other sides. In addition, there was a small, two-stranded b sheet involving residues 41 to 43 and 136 to 138 at the C terminus of the domain.
The KBD of MKP7 shares 35% and 32% sequence identity with that of MKP3 and MKP5, respectively. Although the KBDs of MKP7 and MKP3 have greater sequence similarity, differences in KBD structures do not fall strictly on MKP7 compared to MKP3 and MKP5 lines. The KBD structure of MKP7 is more similar to MKP5 (RMSD, 1.5 Å) than to MKP3 (RMSD, 8.0 Å) (Fig. 5, B and C) . There are differences in many of the surface loops and helices between the KBD structures of MKP3 and MKP7 (Fig. 5B) . The positively charged residues and F A -X-F B motif that are important for MAPK binding are located in different positions in the two structures. In contrast to MKP3, the KBD structure of MKP7 (residues 5 to 138) closely resembles that of MKP5 (Fig. 5C ). In particular, the key residues on the helices a2 and a3′ are well conserved between these two domains, suggesting a possible similarity in the interaction mode between MKP7 and p38a (Fig. 5D ). To further test this hypothesis, we generated forms of the MKP7 KBD bearing mutations corresponding to those we made on MKP5 on the basis of sequence and structural alignment and examined their effects on MKP7 phosphatase activity ( Fig. 5E and table  S3 ). As expected, the V63A and I65A MKP7 mutants showed little or no difference in phosphatase activity, whereas the other mutants showed reduced specific activities of MKP7. Thus, MKP7 binds p38a in a docking mode similar to that of MKP5, and the interaction model can be generated by superimposition of KBD MKP7 to the corresponding domain of MKP5 in the complex (Fig. 5F ). Given the relatively higher sequence identity (40%) between MKP7 and hVH5 (also known as M3 or M6) (30) , and because residues involved in the protein-protein interaction are highly conserved (Fig. 5G) , it is reasonable to postulate that the new binding mode is conserved in this cytoplasmic and p38-and JNK-specific MKP subgroup (MKP5, MKP7, and hVH5).
DISCUSSION
The p38a MAPK signaling pathway plays an important role in inflammation and many other physiological processes. It has been the subject of extensive efforts in both basic research and drug discovery to make specific inhibitors of p38a for the treatment of inflammatory diseases such as psoriasis, rheumatoid arthritis, and chronic obstructive pulmonary disease (31-33). Many adenosine 5′-triphosphate (ATP)-competitive smallmolecule inhibitors directed against p38a have been described and tested (34) . Although some of these inhibitors show anti-inflammatory effects in animal models, the side effects have limited their clinical utility. The repeated failure of the current p38a inhibitors in clinical trials raises the need for additional modes of specifically interfering with kinase activity. MAPK docking sites are emerging as possible targets for drug design, because MAPKs use docking interactions to link module components and bind substrates. Docking site-directed inhibitors could block the function of a specific MAPK pathway by inhibiting both MAPKK binding and substrate binding. This strategy has opened a new way for the development of protein kinase inhibitors targeting substrate-specific docking sites, rather than the highly conserved ATP binding sites. Here, we report the crystal structure of the MAPK p38a in complex with the KBD of the phosphatase MKP5. Our structure reveals that the binding mode of p38a to its cognate phosphatase is distinct from that observed for the recognition of ERK2 by the KBD of MKP3. The KBD of MKP5 also binds in the p38a docking groove, but the major difference with the ERK2-KIM MKP3 complex is the reversed direction of the peptide backbones of MKP5 compared to MKP3. Accordingly, although both p38a and ERK2 use a cluster of highly conserved basic residues to bind to their respective KBDs, the reverse orientations in each case imply the involvement of a whole new set of hydrophobic residues. Indeed, although such hydrophobic residues are located C-terminal to the cluster of basic residues in MKP3, they are found N-terminal to the corresponding cluster in MKP5. Additionally, the region within the KBD of MKP3 that directly docks onto ERK2 adopts an extended conformation, whereas the regions within the KBD of MKP5 in contact with p38a adopt a-helical conformations, resulting in a different interacting mode. We also determined the crystal structure of the KBD of MKP7, another member of the cytoplasmic and p38-and JNK-specific MKP subgroup. The KBD structure of MKP7 closely resembles that of the MKP5 KBD, suggesting that the mechanism of molecular recognition by the KBD of MKP5 is conserved in this MKP subgroup. Biochemical data provide further support to this notion.
In summary, our finding sheds new light on the molecular basis of MAPK-MKP interactions, helps to better understand the regulation of MAPKs, and may provide invaluable information to exploit highly selective p38a inhibitors for innate and adaptive immune diseases.
MATERIALS AND METHODS
Protein expression and purification
Expression and purification of N-terminally (His) 6 -tagged unphosphorylated p38a was performed as previously described (21) . For the KBD of 
MKP5 (KBD
MKP5
) construct, the complementary DNA (cDNA) encoding residues 139 to 287 of the human MKP5 was subcloned into the expression vector pET21b (Novagen) with the restriction sites Nde I and Xho I. The recombinant protein carried a hexahistidine tag at the C terminus. The plasmid was transformed into Escherichia coli strain BL21, and cultures were grown in LB medium at 37°C to an OD 600 (optical density at 600 nm) of 0.8 and induced with 0.2 mM isopropyl-b-D-thiogalactopyranoside (IPTG) at 20°C for 14 hours. Cells were collected by centrifugation and lysed by sonication. The protein was first isolated by means of an affinity Ni-NTA column (Qiagen) and eluted with 300 mM imidazole. The eluted sample was subsequently subjected to a cation exchange SOURCE 15S column (GE Healthcare) and eluted with a NaCl gradient up to 1 M. The p38a-KBD MKP5 complex was prepared by mixing the purified proteins with KBD MKP5 present in slightly molar excess (1:1.5 molar ratio); the p38a-KBD MKP5 complex was purified by size exclusion chromatography using a Superdex 200 (S200, GE Healthcare) column equilibrated in a buffer containing 10 mM Hepes (pH 7.5), 150 mM NaCl, and 2 mM dithiothreitol (DTT). Purified protein was flash-frozen in liquid nitrogen and stored at −80°C.
For the KBD of MKP7 (KBD MKP7 ) construct, the cDNA encoding residues 5 to 138 of the human MKP7 was subcloned into the expression vector pET21b (Novagen) with the restriction sites Nde I and Xho I. The C-terminally (His) 6 -tagged KBD MKP7 was overexpressed in E. coli BL21(DE3) with 0.2 mM IPTG induction at 20°C for 14 hours. The KBD MKP7 was first purified by an Ni-NTA column and anion exchange SOURCE 15Q column and was further purified with a Superdex 200 column equilibrated in 10 mM Hepes (pH 7.5), 150 mM NaCl, and 2 mM DTT. Purified protein was flash-frozen in liquid nitrogen and stored at −80°C.
Protein crystallization and data collection
Crystals of p38a-KBD MKP5 complex were obtained at 22°C in 5 days by means of the hanging-drop technique using equal volumes of protein solution and reservoir buffer [100 mM tris (pH 7.5 to 8.0), 8 to 12% (w/v) polyethylene glycol 3350, and 8 to 12% (w/v) sucrose]. Fresh crystals were quickly transferred to a cryoprotectant buffer containing 20% ethylene glycol before snap-freezing in liquid nitrogen before data collection. Diffraction data were collected at the Shanghai Synchrotron Radiation Facility (SSRF) BL17U beamline and processed with HKL2000 (35) . The crystals belonged to space group P4 1 2 1 2 with unit cell dimensions of a = b = 72.4 Å, c = 226.1 Å, and a = b = g = 90°. There was one 1:1 p38a-KBD MKP5 complex in the asymmetric unit. Crystals of KBD MKP7 were obtained at 22°C in 2 days with the hanging-drop technique using equal volumes of protein solution and reservoir buffer [100 mM bis-tris (pH 5.7 to 6.2), 24 to 28% (w/v) polyethylene glycol 3350, and 0.1 M ammonium sulfate]. Microseeding was used to produce single crystals. Diffraction data were collected on a home lab x-ray system and processed with HKL2000. The crystals belonged to space group P1 with unit cell dimensions of a = 40.5 Å, b = 47.5 Å, c = 64.5 Å, and a = 91.2°, b = 97.3°, g = 96.8°. There were four molecules of KBD MKP7 in the asymmetric unit.
Structure determination and refinement
The crystal structure of p38a in complex with KBD of MKP5 was determined by molecular replacement using Phaser (36) with the search models of unphosphorylated p38a [Protein Data Bank (PDB) ID 1P38] and apo KBD of MKP5 (PDB ID 2OUC). The crystal structure of KBD MKP7 was solved by molecular replacement using Phaser with the search model of apo KBD of MKP5 (PDB ID 2OUC). The initial solution of either structure was subjected to multiple cycles of coordinates, simulated annealing, individual B factors, and TLS (translation-libration-screw) groups with PHENIX (37) and to manual refinement with Coot (38) . The crystallographic R factor and free R factor were finally reduced to 21.6% and 26.0%, respectively, at 2.7 Å resolution for the p38a-KBD MKP5 complex and 23.9% and 28.8% for KBD MKP7 at 2.67 Å resolution. PROCHECK (39) indicated that none of the residues in either structure is in the disallowed region of the Ramachandran plot. Details of the data collection and refinement statistics for the complex are summarized in Table 1 . All figures displaying the protein structures were prepared with PyMOL software from Delano Scientific (http://www.pymol.org).
Generation of MKP5 and MKP7 mutants and phosphatase activity assays
The mutants were generated by polymerase chain reaction (PCR) oligonucleotide site-directed mutagenesis, and all mutations were confirmed by DNA sequencing. The MKP5 mutants were expressed and purified as previously described for the wild-type protein (21) . Because we could not obtain soluble protein of full-length MKP7 expressed in bacteria, we subcloned into the expression vector pET21b the cDNA encoding residues 5 to 303 of the human MKP7 containing the KBD and catalytic domains but without the C-terminal PEST-like sequence (Fig. 4A) . Deletion of the C-terminal PEST-like sequence has no effect on the binding ability and phosphatase activity of MKP7 toward MAPKs (28) . Therefore, to access the binding mode between KBD of MKP7 and p38a, we generated mutations in MKP7 (5 to 303) corresponding to those on MKP5 and examined their effects on phosphatase activity toward bisphosphorylated p38a. The C-terminally His 6 -tagged MKP7 (5 to 303) and its mutants were expressed in E. coli BL21(DE3) and purified using standard procedures and an Ni-NTA column, followed by a cation exchange SOURCE 15S column. All proteins prepared were examined by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) analysis, and the contents of each were judged at least 90% pure. The purified protein was combined with 20% glycerol and stored at −80°C. Protein concentrations were determined spectrophotometrically using theoretical molar extinction coefficients at 280 nm.
MKP5 and MKP7 phosphatase activity toward bisphosphorylated p38a was measured by a continuous spectrophotometric assay (21, 40) . This assay incorporates a coupled enzyme system, which uses purine nucleoside phosphorylase and its chromogenic substrate 7-methyl-6-thioguanosine (MESG) for the quantification of inorganic phosphate produced in the phosphatase reaction (41) . All experiments were carried out at 25°C in 1.8-ml reaction mixture containing 50 mM Mops (pH 7.0), 100 mM NaCl, 0.1 mM EDTA, 100 mM MESG, and purine nucleoside phosphorylase (0.1 mg/ml). The reactions were initiated by the addition of phosphatase. The time courses of resulting absorbance change at 360 nm were recorded on a PerkinElmer LAMBDA 45 spectrophotometer equipped with a magnetic stirrer in the cuvette holder. Initial rates were determined from the linear slope of progress curves obtained, and the experimental data were analyzed with a nonlinear regression analysis program. Quantitation of phosphate release was determined with the extinction coefficient of 11,200 M −1 cm −1 for the phosphate-dependent reaction at 360 nm at pH 7.0 (42). The concentration of MESG was determined at 331 nm, using a molar extinction coefficient of 32,000 M −1 cm −1
. MKP5 and MKP7 (as a control) and mutants were assayed with the same procedure mentioned above.
p38a and KBD interactions
Size exclusion chromatography was performed to determine the apparent molecular weight of p38a alone, KBD of MKP5 or MKP7 alone, and mixture of the two (with KBD present in roughly fivefold molecular excess).
Each sample (0.1 ml) was loaded onto a Superdex 200 column, preequilibrated in the buffer [50 mM Hepes (pH 7.5), 150 mM NaCl, and 2 mM DTT], and run at 4°C using a flow rate of 0.5 ml/min. The column was calibrated with the molecular weight markers.
Kinetic analysis of competitive binding assays to determine the binding affinity of KBD for phosphorylated p38a
Because KBD MKP5 binds p38a tightly, we believe that this domain may compete with full-length MKP5 for p38a binding. The postulated scheme is shown below.
where S represents substrate bisphosphorylated p38a, and E and I represent the enzyme (full-length MKP5) and inhibitor (the KBD domain of MKP5), respectively. K S and K i are the dissociation constants for the phosphorylated p38a to full-length MKP5 and its KBD domain, respectively, and k cat is the turnover number.
The velocity equation is given by 
The mass balance equations for S and I are
The mass balance equations assume that the concentration of S complexed with the enzyme is negligible.
Substituting for [I] and [SI] in the expression for K i :
The negative solution of the square root can be ignored because [S] must be a positive number.
The expression for [S] can then be substituted into the velocity equation:
We carried out the competitive binding assays and determined the binding affinities of KBD MKP5 and KBD MKP7 for phosphorylated p38a, respectively. The initial rates of MKP5-catalyzed reactions were measured in the presence of various concentrations of inhibitor KBD and substrate p38a. Figures 1D and 4C respectively show the dependence of the initial velocity on p38a concentration at four different fixed KBD MKP5 and KBD MKP7 concentrations, which revealed that both KBD domains inhibit the MKP5 activity in a concentration-dependent manner. The data sets of initial velocities were analyzed with Eq. 1 by a global fitting procedure. The kinetic parameters for KBD MKP5 were determined to be K S = 0.065 ± 0.009 mM, K i = 1.01 ± 0.01 mM, and k cat = 0.585 ± 0.014 s , and those for KBD MKP7 were K S = 0.070 ± 0.001 mM, K i = 0.74 ± 0.13 mM, and k cat = 0.600 ± 0.014 s , respectively.
p38a kinase activity assays
The kinase activity of phosphorylated p38a was measured spectrophotometrically with ATF2D109 or EGFR peptide as substrate (43) . This assay couples the production of adenosine 5′-diphosphate (ADP) with the oxidation of NADH [reduced form of nicotinamide adenine dinucleotide (NAD + )] by pyruvate kinase (PK) and lactate dehydrogenase (LDH). The standard assay was carried out at 25°C in 1.8-ml reaction mixture containing 50 mM Mops (pH 7.0), 100 mM NaCl, 0.1 mM EDTA, 10 mM MgCl 2 , 0.2 mM NADH, 1.0 mM phosphoenolpyruvate, LDH (20 U/ml), and PK (15 U/ml), 1 mM ATP, 30 or 12 nM phosphorylated p38a, and 4 mM ATF2D109 or 100 mM EGFR peptide. The progress of the reaction was monitored continuously by following the formation of NAD + at 340 nm on a PerkinElmer LAMBDA 45 spectrophotometer equipped with a magnetic stirrer in the cuvette holder. The concentration of ADP produced in the phosphorylated p38a-catalyzed reaction was determined using an extinction coefficient for NADH of 6220 cm Table S1 . Kinetic parameters of full-length MKP5 and its catalytic domain toward phosphorylated ERK2 or p38a. Table S2 . Kinetic parameters of full-length MKP5 and its mutants with phosphorylated p38a as substrate. Table S3 . Kinetic parameters of MKP7 (residues 5 to 303) and its mutants with phosphorylated p38a as substrate. References
